Beckman Coulter a global leader in Life Sciences and Diagnostic instrumentation is planning to ramp up its commercial focus on the Indian subcontinent.
Ganesh Ramaswamy, Senior Vice President, High Growth Markets, Beckman Coulter Diagnostics said, “India is one of the fastest growing markets in diagnostics field and has its own unique opportunities and challenges. In order to address these opportunities and provide customized solutions that cater to the Indian market, we have decided to carve out India into a separate region of focus. This will ensure that we are much more attentive to our customers’ feedback and are able to accelerate our timelines in rolling out products, services and solutions based on local requirements.”
As a first step, the company recently launched its compact five-parthematology analyzer – the DxH 500 which is perfectly suited for over 15,000 small to mid-sized laboratories spread across the country. This cost effective analyzer will make state-of-the-art technology more affordable to not just Tier 2 and Tier 3 labs but also for smaller laboratories within metropolitan cities.
Ganesh Ramaswamy, Senior Vice President, High Growth Markets, Beckman Coulter Diagnostics said, “India is one of the fastest growing markets in diagnostics field and has its own unique opportunities and challenges. In order to address these opportunities and provide customized solutions that cater to the Indian market, we have decided to carve out India into a separate region of focus. This will ensure that we are much more attentive to our customers’ feedback and are able to accelerate our timelines in rolling out products, services and solutions based on local requirements.”
Beckman Coulter Diagnostics plans to ramp up its presense in India pic.twitter.com/sEaEsNTHxG— Press Release Watch (@PrReleaseWatch) June 28, 2016
As a first step, the company recently launched its compact five-parthematology analyzer – the DxH 500 which is perfectly suited for over 15,000 small to mid-sized laboratories spread across the country. This cost effective analyzer will make state-of-the-art technology more affordable to not just Tier 2 and Tier 3 labs but also for smaller laboratories within metropolitan cities.
